- During Dry Eye Awareness Month, Alcon brings attention to
the link between screen time and eye dryness complaints
- Survey reveals nearly 80% of Americans are spending more
time on screens because of COVID-19 pandemic, and of those who do,
nearly half have experienced their eyes feeling dry as a
result
- SYSTANE® HYDRATION Preservative-Free (PF) with HydroBoost
Technology joins SYSTANE family of dry eye products, now available
online and in retail stores nationwide
Alcon, the global leader in eye care dedicated to helping people
see brilliantly, today announced the results of a new survey,
rolled out in recognition of Dry Eye Awareness Month. The survey,
conducted by research firm Ipsos among 1,005 nationally
representative U.S. adults, uncovers the impact the COVID-19
pandemic is having on consumers’ screen time and how that impacts
their perceptions on eye health. Key findings include:
- Nearly 80% of Americans reported their screen time increased
during the COVID-19 pandemic.
- Three out of five (60%) of those who have increased their
screen time are concerned about the impact that increased screen
time will have on their eyes.
- Among those with increased screen time, nearly half (45%)
reported their eyes feel dry as a result of it.
“I’ve recently seen a growing number of patients who suffer from
dry eye and eye strain issues linked to extra screen time and less
blinking,” said Dr. Scott Schachter, OD, founder of the private
practice Advanced Eyecare in Pismo Beach, California. “Dry Eye
Awareness Month is the perfect time to educate patients on the
signs and symptoms of dry eye—including fluctuating vision, burning
or irritated eyes—and remind them about caring for their eyes.
Simple habits like taking breaks every 20 minutes and looking 20
feet away for 20 seconds, and using an over-the-counter eye drop
for an added boost of hydration, like the SYSTANE family, can help
dry eye sufferers find relief.”
SYSTANE® HYDRATION Preservative-Free (PF) lubricant eye drops,
the latest product in the SYSTANE family of drops, is now available
nationwide. It delivers a new option for dry eye sufferers who may
be using drops with increased frequency as screen time increases
for many Americans who are spending more time at home due to the
COVID-19 pandemic. SYSTANE HYDRATION with HydroBoost technology
provides extra moisture and long-lasting dry eye relief for those
with sensitive, dry eyes, and especially those who use drops more
than four times a day. SYSTANE HYDRATION is for use as a protectant
against further irritation or to relieve dryness to the eye.
“Over 30 million people in the U.S. suffer from dry eye,1 and
this survey shows us that increased screen time is associated with
symptoms of eye dryness,” said Sergio Duplan, President, Alcon
North America. “We know many people are looking for
over-the-counter products to provide relief for their dry eye
symptoms and Alcon is proud to add SYSTANE HYDRATION as the newest
option in our SYSTANE family of eye drops.”
SYSTANE HYDRATION PF is preservative-free and features
proprietary HydroBoost Technology, an exclusive combination of
inactive ingredients that help retain the dual active lubricants on
the ocular surface.2,3 It is available in 30 single-use vials in
select retail stores and online at systane.myalcon.com.
This new eye drop joins the portfolio of SYSTANE products,
including SYSTANE® Complete.
Survey Methodology These are
findings of an Ipsos poll conducted between July 7 - 8, 2020, on
behalf of Alcon. For this survey, a sample of 1,005 adults age 18+
from the continental U.S., Alaska, and Hawaii was interviewed
online in English. The poll has a credibility interval of plus or
minus 3.5 percentage points for all respondents.
Important Information for the
Systane® Family of Products Systane® lubricant eye
drops have been clinically proven to reduce the symptoms of dry
eye, providing immediate, long-lasting protection and comfort. The
Systane® brand is the best-selling dry eye franchise in artificial
tear solutions and is the #1 doctor-recommended brand. Systane®
Complete is a treatment option for people who suffer from
evaporative dry eye, aqueous tear-deficient dry eye or mixed dry
eye. While Systane® Ultra is designed for dry eye with aqueous
deficient patients, Systane® Balance lubricant eye drops are
designed specifically for patients with dry eye associated with
Meibomian gland dysfunction.
Cautionary Note Regarding
Forward-Looking Statements This press release contains
“forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: “anticipate,” “intend,” “commitment,” “look
forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,”
“should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
ABOUT ALCON Alcon helps
people see brilliantly. As the global leader in eye care with a
heritage spanning more than seven decades, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 20,000 associates are enhancing
the quality of life through innovative products, partnerships with
eye care professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
References 1. Tear Film and
Ocular Surface Society (TFOS). TFOS DEWS II. Available at
http://www.tearfilm.org/detreports-tfos_dew_ii_reprot/32_30/eng/.
Accessed May 9, 2018. 2. Mrukwa-Kominek E, Baranska K, Jadczyk K.
FIrst clinical reports on the application of the modern
dual-polymer formula in aqueous deficiency dry eye syndrome -
Polish observations. Presented at the 20th European Society of
Cataract & Refractive Surgery Winter Meeting; February 26-28,
2016; Athens, GR. 3. Jones L, Downie LE, Korb D, et al. TFOS DEWS
II management and therapy report. Ocul Surf. 2017;15:575-628.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200721005237/en/
Investor Relations Christina
Cheng + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Blake Overby
+ 1 817 551 4328 (Office) + 1 682 321 2897 (Mobile)
Blake-1.Overby@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024